靶向侵袭性乳腺癌亚型中的 IL-13 受体 α2 与 EphA2：特别关注 CAR-T 细胞治疗

Breast cancer (BCA) remains the leading cause of cancer-related mortality among women worldwide. This review delves into the therapeutic challenges of BCA, emphasizing the roles of interleukin-13 receptor 2 (IL-13R 2) and erythropoietin-producing hepatocellular receptor A2 (EphA2) in tumor progression and resistance.

Highlighting their overexpression in BCA, particularly in aggressive subtypes, such as Her-2-enriched and triple-negative breast cancer (TNBC), we discuss the potential of these receptors as targets for chimeric antigen receptor T-cell (CAR-T) therapies.

We examine the structural and functional roles of IL-13R 2 and EphA2, their pathological significance in BCA, and the promising therapeutic avenues their targeting presents. With an in-depth analysis of current immunotherapeutic strategies, including the limitations of existing treatments and the potential of dual antigen-targeting CAR T-cell therapies, this review aims to summarize potential future novel, more effective therapeutic interventions for BCA.

Through a thorough examination of preclinical and clinical studies, it underlines the urgent need for targeted therapies in combating the high mortality rates associated with Her-2-enriched and TNBC subtypes and discusses the potential role of IL-13R 2 and EphA2 as promising candidates for the development of CAR T-cell therapies.